Home›Stocks›SOPH

SOPH — structural market context

SOPHiA GENETICS SA

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 23. Each line shows the earlier value, the later value and their dates.

Price

Close $7.35 (Oct 23) vs $7.05 (Oct 22): +4.26%.

Volume

0.73× its 20-session average (628K) on Oct 23.

Includes pre- and post-market trading.

Short interest

Short interest 1.1M shares (settlement Sep 30) vs 1.1M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 6 days with fails, largest 30K shares on Sep 29.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 6 days with fails, largest 127K shares on Sep 3.

No new publication in this window.

Insider filings (Form 4)

None recorded in this window.

SOPH events and their magnitude

Latest SEC filing in the event study

Form 4 · sale · filed 2026-10-14 · View on sec.gov ↗

…

Open the Event Study →

SOPH short interest & days to cover

SHARES SHORT
1.1M
% OF FLOAT
1.7%
DAYS TO COVER
1.7
CHANGE VS PRIOR
+4.8%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (24d ago)

SOPH fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 24d843$8.3
2026-09-29 · 25d30K$8.49
2026-09-28 · 26d696$8.34

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

SOPH insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 31 sales

InsiderTypeSharesValueFiled
Menu Philippe · officer: Chief Medical OfficerSale (S)5K$36K2026-10-14
Xu Zhenyu · officer: Chief Scientific OfficerSale (S)4K$29K2026-10-14
Camblong Jurgi · director, officer: Executive ChairmanSale (S)9K$62K2026-10-14
Verma Abhimanyu · officer: Chief Technology OfficerSale (S)5K$43K2026-10-07
Xu Zhenyu · officer: Chief Scientific OfficerSale (S)7K$60K2026-10-07

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Frequently asked questions

What is SOPH's short interest?
As of the FINRA settlement date 2026-09-30, SOPH had 1.1M shares sold short — 1.7% of its float, with 1.7 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying SOPH?
In the last 12 months of SEC Form 4 filings, SOPH recorded 0 insider purchases and 31 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
Is this page telling me to buy or sell SOPH?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with S

SAFX · XCF Global, Inc.SAH · Sonic Automotive, Inc.SAM · Boston Beer CompanySARO · StandardAero, Inc.SCHW · The Charles Schwab CorporationSDGR · Schrodinger, Inc.All S →

SOPH: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.